Background Opioid substitution therapy (OST) has been established as the gold standard in
treating opioid use disorders. Nevertheless, there is still a debate regarding the qualitative …

Background People who inject drugs (PWID) experience barriers to accessing testing and
treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an …

Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections
(ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive …

The aim of this analysis was to evaluate perceived barriers related to HCV testing,
management and treatment among physicians practicing in clinics offering opioid agonist …

Background People who use drugs (PWUD) frequently delay or avoid obtaining medical
care in traditional healthcare settings. Through a randomized controlled trial, we …

Aims To estimate adherence and response to therapy for chronic hepatitis C virus (HCV)
infection among people with a history of injecting drug use. A secondary aim was to identify …

Background Understanding factors associated with engagement across the hepatitis C virus
(HCV) cascade of care (CoC) among people who inject drugs (PWID) is critical for …

Background: New technologies and therapies allow the possibility of a single-visit test and
treat model for hepatitis C virus (HCV), addressing some of the barriers to care faced by …

Background While the public health benefits of new HCV treatments depend on treatment
adherence, particularly among people who inject drugs (PWID), several social and medical …

Abstract Background Hepatitis C virus (HCV) direct-acting antiviral therapy is effective
among people receiving opioid substitution therapy (OST), but studies are limited by small …